Serum p53 antibody in breast cancer

Yamamoto, Shinya; Chishima, Takashi; Adachi, Shouko; Harada, Fumi; Toda, Yoshitomo; Arioka, Hitoshi; Hasegawa, Naoki; Kakuta, Yukio

doi:10.3233/cbm-140396

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the development of novel molecular markers is required, using blood testing as a non-invasive method. The serum anti-p53 antibody (Ap53Ab) has been applied as a novel tumor marker for the detection of several cancers, including esophageal cancer (1,2), breast cancer (1,3) and CRC (1,4,5), from 2007 onwards in Japan. Mutations of the TP53 gene, which were detected in half of CRC cases (6), were strongly associated with carcinogenesis.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Kumamoto

Ishida

Kuwabara

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the usefulness of serum anti-p53 antibody (Ap53Ab) measurement for the diagnosis of colorectal cancer (CRC), and the clinical significance of the association between Ap53Ab expression and survival rate. Ap53Ab, carcinoembryonic antigen (CEA) and carbohydrate antigen (CA)19-9 were measured by ELISA in 674 CRC patients and 115 healthy volunteers (control group). The half-life time of Ap53Ab and CEA was calculated. The association between positive Ap53Ab expression and clinicopathological characteristics, including survival rate, was analyzed. Of the 674 CRC patients, 195 (28.9%) were positive for Ap53Ab expression, while the positive rates of CEA and CA19-9 level were 39.9 and 16.9%, respectively. Positivity for Ap53Ab alone was observed in 94 patients (13.9%), whereas the positivity rate of any markers examined was 58.7%. The mean half-life of Ap53Ab and CEA was 30.7 and 11.3 days, respectively. Positive expression of Ap53Ab was significantly associated with the depth of tumor invasion (P<0.001), lymph node metastasis (P=0.024), stage (P<0.001) and CEA level (P= 0.005). No significant correlation between Ap53Ab expression and poor survival rate was observed. The positive rate of Ap53Ab was higher compared with that of CEA and CA19-9 in early-stage CRC. The combination of these markers improved the diagnostic yield of CRC up to ~60%. Furthermore, Ap53Ab expression was associated with lymph node metastasis, but not with shorter survival. These results indicated that the measurement of Ap53Ab may contribute to increased rate of detection of CRC, particularly in patients with early-stage disease, in clinical practice.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Kumamoto

Ishida

Kuwabara

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Moreover previous reports demonstrated that serum appearance of p53Abs could be indicator for progressive potential of breast cancer, including more frequent incidence for axillary lymph node metastasis and larger sizeof the breast tumors, more unfavorable prognosis of the patients (16), less favorable effectiveness derived from anthracycline -based chemotherapy for the tumors (17), and higher incidence of the pathological triple negative breast cancer (TNBC), that are absolutely negative for expression of hormone receptors (ER and PgR) and HER2 and is known to have a more aggressive potential compared with other pathological type of breast IDC (2,3).…”

Section: Discussionmentioning

confidence: 99%

“…Serum appearance of p53 antibodies can be appreciated as a similarly identified aspect of p53 gene mutations (1,2), and its significance as an indicator of progressive potential of the tumors has been reported in some human malignant tumors including breast cancer (2,3).…”

Section: Introductionmentioning

confidence: 99%

Further evidence to demonstrate the significance of serum appearance of anti-p53 antibody as a marker for progressive potential in invasive ductal carcinoma of the breast

Nozoe

Kono

et al. 2017

J. Med. Invest.

View full text Add to dashboard Cite

: Background : Serum appearance of anti-p53 antibody (p53Ab) has been reported as an indicator for progressive potential of human tumor tumors including breast cancer. But its significance in breast cancer has not been discussed fully. Methods : Relationship between serum appearance of p53Abs and representative data accounting for progressive potential in breast cancer, nuclear grade (NG), triple negative cancer, and the cumulative score based on these two data (TGS) was investigated among 129 women with invasive ductal carcinoma (IDC) of the breast, who had been treated with surgical resection. Results : There was a significant correlation between appearance of p53Abs and recurrence of the tumors (P = 0.035). Significant correlation of serum appearance of p53Abs with negative expression of ER (P = 0.011), the proportion of TNBC (P = 0.013), NG (P = 0.017), and TGS (P = 0.0005). Conclusions : Preoperative serum appearance of p53Abs can be correlated with pathological nuclear grade, incidence of triple negative breast cancer, and TGS. These results might demonstrate more powerful significance of serum appearance of p53Abs as an indicator of progressive potential in IDC of the breast.

show abstract

Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1

Kikuchi,

Shimada,

Hatanaka

et al. 2023

Int J Clin Oncol

View full text Add to dashboard Cite

Serum p53 antibody in breast cancer

Abstract: Measurement of anti-p53 antibodies is useful for the prevention of oversight in the evaluation of multiple and/or bilateral breast cancer.

Cited by 3 publications

References 15 publications

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Clinical significance of serum anti-p53 antibody expression following curative surgery for colorectal cancer

Further evidence to demonstrate the significance of serum appearance of anti-p53 antibody as a marker for progressive potential in invasive ductal carcinoma of the breast

Clinical practice guidelines for molecular tumor markers, 2nd edition review part 1

Contact Info

Product

Resources

About